Rheumatoid Arthritis.Pre-Clinical / Designed

The mechanism we're betting on.

Synovial inflammation, autoimmune T-cell axis, and microbiome-driven inflammation. Designed for biologic-naive and post-biologic-failure cohorts with bDMARD-bridge and combination arms. The full mechanism map — including compound list, dose escalation, pre-specified biomarker thresholds, and the cross-walk modifiers used when re-fitting blends from related indications — is part of the gated methodology pack.Gated

What the rest of the world is doing.

Numbers below are surfaced by Atlas Bio's ClinicalTrials.gov and PubMed RWE pipelines, run against the Rheumatoid Arthritis indication. Counts are industry-wide trials registered on ClinicalTrials.gov, not Atlas Bio studies. Methodology →

Locked before readout.

Predictions for this study are SHA-256 locked before any readout. Pre-registration covers target engagement, primary endpoint, secondary endpoints, and the falsification criterion. The hash, prediction wording, and timestamp are available to verified clinicians and indication researchers on request.Gated

Same stack, every indication.

• M2 · Pre-Registration — SHA-256 locking before readout.
• M1 · IBC Reasoning — 19-agent audit (11 core + 8 reasoning nodes).
• M3 · Cross-Trial Validation — mechanism-anchored bridging across indications.
• M4 · RWE Pipelines — ClinicalTrials.gov, PubMed, FDA, EDGAR feeds (the source of the numbers above).